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Abstract Niemann Pick disease type C (NP-C) is a rare
autosomal recessive disorder that results from mutations in
either the NPC1 or the NPC2 gene. The estimated incidence
of NP-C is 1 in 120,000 live births, although the frequency of
cases is higher in some isolated populations. More than 350
different NPC1 and NPC2 gene mutations have been
reported in patients with confirmed diagnoses. Approxi-
mately 95 % of patients harbour mutations in NPC1, with
most of the remaining patients having NPC2 mutations. The
traditional methods for diagnosing patients with NP-C
include histopathological analysis of bone marrow aspirate,
liver and skin biopsies, fluorescent and electron microscopy,
and cholesterol esterification assays. New laboratory meth-
ods that use mass spectroscopy for detection of cholesterol
metabolism products are promising to become part of the
routine diagnostic and screening tests in the near future, but
further evaluation is required to determine the sensitivity and
specificity of these analyses in patients with different age-at-
onset forms of NP-C. Although filipin staining and choles-
terol esterification studies performed in patient skin fibro-
blasts can, in experienced hands, provide a robust approach
to diagnosing NP-C, they are only available in a few spe-
cialist laboratories. Thus, sequencing of NPC1 and NPC2 is
currently the most universally accessible diagnostic tech-
nique in this disorder.
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Introduction
Niemann Pick disease type C (NP-C; OMIM#257220 and
OMIM#607625) is a rare autosomal recessive, multisys-
temic, neurodegenerative condition caused by mutations in
the NPC1 or the NPC2 gene. NP-C is also described as a
neurovisceral disorder, as it affects visceral organs such as
liver, spleen and lungs as well as the central and the
peripheral nervous systems [28].
Clinical presentation varies greatly between patients in
terms of age-at-onset and the type/severity of clinical
symptoms, as well as in the speed of neurodegeneration.
The incidence of NP-C is estimated to be
1:100,000–120,000 live births in France, the UK and
Germany. However, studies in certain isolated populations
have revealed a higher carrier frequency, as reported
among Acadiens in Nova Scotia, Hispanics from Southern
Colorado and New Mexico, and Greeks on a small Aegean
island [21, 24, 38, 42]. The greater carrier frequency in
these populations led to increased numbers of patients
being detected.
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The cellular pathology of NP-C is characterised by
abnormal intracellular trafficking of cholesterol and other
related lipids, with accumulation of unesterified cholesterol
and other lipid moieties in lysosomes and late endosomes
[29, 30, 36]. While the precise functions of the protein
products encoded by the NPC1 and NPC2 genes have not
yet been determined, it is believed that they may function
in a co-operative fashion in the lysosomal/late-endosomal
trafficking of cholesterol and other molecules [17, 35].
Other reviews in this supplement address the clinical
features of NP-C in the context of current international
disease management guidelines. In this review, we focus
on the genetic and laboratory diagnostic approaches that
can be applied when NP-C is suspected. The appropriate
use of clinical and laboratory diagnostic methods addressed
here will help to identify and treat patients early in the
course of the disease.
Genetics of NP-C
Carstea et al. [6] located NPC1 on chromosome 18q11-q12
and first identified mutations in NPC1 in patients with NP-
C. The NPC1 gene encodes a 1278 amino acid protein that
belongs to a family of membrane-bound proteins with
sterol-sensing domains. The complete NPC1 genomic
sequence consists of 57,052 kb [3]. The C-terminal section
of NPC1 protein has sequence similarity to the Patched
morphogen receptor. Topologic studies showed that it has
13 transmembrane domains and three hydrophilic luminal
loops [12]. It was found that in monkey brain, NPC1 pre-
dominantly localises to late endosomes in presynaptic
astrocytic glial processes [27]. Later studies concluded that
neuropathology and cholesterol accumulation in NP-C is
related to a defect in late-endosomal trafficking [45]. The
current understanding of the intracellular cholesterol traf-
ficking suggests that endocytosed cholesterol needs to be
transported from late endosomes to the Golgi apparatus and
then to the endoplasmic reticulum (ER) for esterification,
which is essential for cholesterol secretion [8]. In NP-C
cells, where NPC1 function is deficient, unesterified cho-
lesterol and sphingolipids accumulate in late endosomes
and lysosomes.
Lloyd-Evans et al. [18] reported increased storage of
sphingosine and decreased lysosomal calcium levels in cell
models of NP-C, suggesting that NPC1 may be involved in
the lysosomal efflux of sphingosine and that its deficiency
leads to changes in intracellular calcium concentration and
a subsequent endocytic trafficking defect.
More than 300 mutations in NPC1 have been reported so
far, as listed across several mutation databases. There are
also many mutations that were identified in service labo-
ratories that have not been reported in the literature. The
most up-to-date database, the Human Gene Mutation
Database (www.hgmd.cf.ac.uk), lists a total of 334 NPC1
defects that include 228 missense and nonsense mutations:
46 small deletions, 26 mutations affecting splicing, 24
small insertions, two small indels, seven gross deletions
and one gross insertion/duplication. This list includes
mutations located in the intronic sequence, which create
additional splice sites [19].
The most common NPC1 mutation, p.I1061T, is detected
in *20 % of NPC alleles among Western Europeans and is
very common in Spanish–American patients from the upper
Rio Grande valley [9, 22, 32]. The mutation p.G992W is
found in the Nova-Scotian cohort of patients that, prior to the
identification of the genetic cause of NP-C, were thought to
have a unique disorder called Niemann Pick disease type D
[11]. This mutation has since been found in patients with
other ethnic origins. The region between amino acids 1038
and 1253, which shares 35 % identity with the patched gene,
appears to be a hotspot for mutations [26]. Because of the
large number of ‘private’ family-specific mutations, it is
challenging to perform genotype–phenotype correlation
studies. However, the presence of nonsense and frameshift
mutations correlates well with the severe neurologic pheno-
type. Some of the missense mutations appear to be associated
with late-onset, slowly progressing disease [22, 34].
Mutations in NPC1 are found in *95 % of patients with
NP-C that underwent mutation testing, whereas only a few
families with NPC2 mutations have been reported so far.
The NPC2 gene is located on chromosome 14q24.3, spans
13.5 Kb, and contains five exons [25]. To date, one non-
sense mutation (E20X) seems to occur more frequently in
published reports [23, 41]. It is difficult to establish any
genotype–phenotype correlation with such a small number
of published reports [7].
The NPC2 gene encodes a small 151 amino acid gly-
coprotein that is ubiquitously expressed and has a lyso-
somal and late-endosomal location [25]. Friedland et al.
[10] determined the crystal structure of NPC2 protein and
showed that it is able to bind the cholesterol analogue,
dehydroergosterol. Further studies showed that NPC2 is a
secreted, soluble protein with a high affinity for cholesterol
[16]: a mutation of one amino acid codon in the NPC2 gene
led to the severe cholesterol trafficking defect that is
characteristic of NP-C. The phenotype of Npc2 knockout
mice was found to be identical to that of the Npc1
knockout, thus confirming that the two proteins are
involved in the same intracellular pathway [35]. This
neurodegenerative phenotype, characterised by excess lipid
storage, was not enhanced in a double Npc1 and Npc2
knockout. Twenty disease-causing mutations have been
reported in patients with NPC2 mutations so far (www.
hgmd.cf.ac.uk) including 15 missense/nonsense mutations,
two mutations affecting splicing and three small deletions.
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The onset and progression of neurological manifesta-
tions often correlate with specific mutations in both NPC1
and NPC2 genes, but this has not been found to be true in
the case of visceral symptoms [39].
Genetic testing for NPC1 and NPC2 mutations
The most frequently employed method of genetic ana-
lysis for NP-C is Sanger sequencing, which utilizes
polymerase chain reaction (PCR) to target the 30 cod-
ing exons, and intron-exon boundaries, of the NPC1 and
NPC2 genes. Alternatively, targeted next-generation
sequencing (NGS) methods may be applied. NGS has the
potential to reduce costs associated with genetic testing
for NP-C, particularly if the genes concerned are inclu-
ded on a multi-gene panel along with other genes con-
sidered relevant to the patient phenotype. Multiple
recent reviews describe various approaches to gene panel
NGS [5, 14].
In general, sequence changes that result in the intro-
duction of premature stop codons (i.e. nonsense, frameshift
and conserved splice-site mutations) produce truncated
mRNA species that are usually targeted for breakdown
(nonsense-mediated decay; NMD) rather than translation
into proteins. Sequence changes that result in small chan-
ges to the protein sequence (missense and in-frame muta-
tions) may also be disease-causing and, as mentioned
above, many of these have been associated with NP-C and
are listed in mutation databases (www.hgmd.cf.ac.uk;
http://npc.fzk.de). Lastly, sequencing may identify intronic
sequence variants that can disrupt RNA splicing and lead to
NMD. However, missense and intronic variants are not
necessarily disease-causing, and several such polymor-
phisms exist in NPC1 and NPC2.
The genetic diagnosis of NP-C requires the identifica-
tion of clearly pathogenic mutations, but many families
have ‘private’ sequence variants that have not been
reported/published. If these sequence variants are missense
or intronic changes, in silico protein and splicing prediction
tools may be employed to assist in assigning their patho-
genicity. Correlation of sequencing results with a patient’s
clinical features and other diagnostic test results is useful
for the interpretation of these cases.
Genomic rearrangements of NPC1, such as exonic
deletions or whole-gene deletions, are a rare cause of the
disease. Testing for this type of mutation requires a
quantitative methodology and is most frequently performed
using multiplex ligation-dependent probe amplification
(MLPA, MRCHolland).
Deep intronic sequence variants, and variants in the pro-
moter regions of NPC1 and NPC2, are likely to be rare causes
of NP-C. However, such defects would not be detected by the
above methods. Full gene sequencing is possible using NGS
methods, but this is likely to identify sequence variants that
are difficult to interpret. Therefore, this strategy should be
limited to patients with a clear clinical and biochemical
diagnosis where no mutations have been identified using
routine sequencing. Investigations of such sequence variants
would require RNA and protein work and, as such, are often
outside the scope of service laboratories.
Other diagnostic procedures
The published international guidelines on the laboratory
diagnosis of NP-C provide a diagnostic algorithm that
proposes the use of the ‘filipin test’ on skin fibroblast
cultures as the first-line specific investigation in patients
with a strong suspicion of NP-C [28, 43]. The guidelines
also suggest that clinical and laboratory features that
should raise a strong suspicion of NP-C include: (1)
abnormal bone marrow aspirate that in some cases may
demonstrate filipin-positive foam cells; (2) elevated plasma
chitotriosidase activities (moderately raised in most cases);
and (3) the presence of (hepato)splenomegaly with normal
activities of acid sphingomyelinase (excluding Niemann
Pick type A and B diseases) and b-glucocerebrosidase
(excluding Gaucher disease). After a positive or equivocal
filipin test, the guidelines suggest NPC1 and NPC2 gene
sequencing, initially testing the common mutation if rele-
vant for the ethnic group in question.
Bone marrow aspirate analysis
Foam cells and sea-blue histiocytes can be found in bone
marrow from NP-C patients. Foam cells show high levels
of unesterified cholesterol when stained with filipin.
However, this test does not have good sensitivity as the
features are not always identified. In addition, patients may
need to undergo repeat bone marrow aspirations before a
diagnostic appearance is detected.
Electron microscopy of skin and liver biopsies
Electron microscopy findings on skin and liver biopsies can
be supportive of the diagnosis of NP-C if vacuolation or
hepatocytes containing ‘myelin figures’ are found [4, 15].
These features are representatives of the accumulated lipids
due to the endo-lysosomal trafficking defect. Nevertheless,
the specificity and sensitivity of these tests are low.
Chitotriosidase assay
The chitotriosidase assay has been proposed as a screening
test for NP-C. However, while it is mildly positive in some
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cases, it can also be normal. Ten per cent of the population
have a pseudodeficiency mutation, which makes this test
uninterpretable [33].
Filipin test
The demonstration of impaired intracellular cholesterol
transport and homeostasis is considered the most specific
functional diagnostic test for NP-C. This test uses skin
fibroblasts cultured in LDL-enriched medium and is able to
detect unesterified cholesterol upon staining with filipin––a
fluorescent chemical compound isolated from an actino-
mycete, Streptomyces filipinensis. Fluorescence micros-
copy of cultured skin fibroblasts from patients with NP-C
usually demonstrates an increased number of vesicles
staining positively with filipin. This appearance is descri-
bed as the ‘classical’ storage pattern and can be identified
in *80–85 % of cases [38].
A smaller proportion of NP-C patients are found to have
less obvious filipin staining, and are described as having a
‘variant’ biochemical phenotype. As discussed above,
several recurrent NPC1 mutations are known to be asso-
ciated with this ‘variant’ phenotype [2, 40]. Heterozygotes
can also show this pattern of cholesterol storage. Notably,
such a variant phenotype, suggestive of ‘possible NP-C’,
can also be seen in patients with sphingomyelinase defi-
ciency (NP-A or NP-B), and other gene defects [2, 40].
Further biochemical testing can be undertaken to mea-
sure the LDL-induced rate of cholesteryl ester formation
[40]. This test detects very low levels of cholesterol
esterification in cell lines with a ‘classical’ biochemical
phenotype, but only a mild or non-significant impairment is
visible in those with a ‘variant’ phenotype [2, 40]. If per-
formed in specialist laboratories with a lot of experience,
these tests have high sensitivity and specificity. However, it
is important to emphasise that ‘variant’ and ‘classical’
appearance on the filipin test do not correlate with clinical
disease severity in NP-C.
Development of new approaches to screening
and diagnosis
Porter et al., looked for evidence of the accumulation of
plasma cholesterol oxidation products (oxysterols) in NP-C
patients, based on observations that oxysterol levels
increase due to raised oxidative stress in multiple tissues in
the mouse model of Npc1 deficiency [37, 44]. These
investigators measured the concentration of cholestane-
3b,5a,6b-triol (3b,5a,6b-triol) and 7-ketocholesterol (7-
KC) in patients with NPC1 mutations, and found that, in
particular, 3b,5a,6b-triol was increased in the plasma of
NP-C patients compared with controls [31]. The same
research group developed a sensitive and specific method
for oxysterol detection using liquid chromatography/tan-
dem mass spectroscopy (LC–MS/MS), and measured
3b,5a,6b-triol and 7-KC in 109 patients with NP-C, 45
obligate carriers and 89 controls [13]. The mean plasma
concentration of 3b,5a,6b-triol in NP-C patients was more
than 5 times higher than in control subjects. However, there
was overlap between measurements from NP-C patients
and those from heterozygote NPC1 mutation carriers [13].
Mean plasma concentration of 7-KC from NPC1 patients
was more than six times higher than the controls, but again
there was overlap with heterozygote carriers. The authors
concluded that although oxysterol assay-based screening
would have a positive predictive value of[97 % in an NP-
C enriched population such as infants with cholestatic liver
disease, this value would fall significantly if the tests were
to be used in the general population.
Alvelius et al. [1] identified very high urine concentration
of a C24 3b-sulfooxy-7b-N-acetylglucosaminyl-5-cholen-
24-oic bile acid (SNAG-D5-CA) together with its glycine
and taurine-conjugates (SNAG-D5-CG, SNAG-D5-CT) in
patients with NP-C compared with controls. As bile acids
can be detected in urine and blood using the LC–MS/MS
approach, the method for the detection of SNAG-D5-CA in
urine was developed and tested by comparing samples from
one adult-onset and one childhood-onset NP-C patient with
11 controls (including two patients with the bile-acid syn-
thesis disorder, 3b-HSD deficiency) [20]. The authors found
that SNAG-D5-CA and its amides were 400 times greater in
the infant NP-C patient and 40 times greater in the 16-year-
old NP-C patient compared with control subjects. The
concentration of SNAG-D5-CA and its metabolites was
increased twofold in patients with 3b-HSD deficiency. The
biochemical pathway for SNAG-D5-CA formation is not yet
clear. It appears that SNAG-D5-CA is conjugated with
GlcNAc at the C-7 residue and that, after exiting the hepa-
tocytes, it is secreted in urine. Although the SNAG-D5-CA
cholesterol elimination pathway is not significant in healthy
subjects, it has a potential to be a major biomarker for NP-C,
although studies that would include much higher numbers of
patients and controls are required to support this.
Summary and suggested diagnostic approach
Technological advances in all areas of biomedical science
have already led to novel treatment developments in many
inherited metabolic diseases that have previously been
considered untreatable. This progress will continue, and
requires parallel improvements in clinical diagnoses. This
is particularly important in neurodegenerative disorders
where early detection and treatment may prevent or lessen
irreversible damage. The worldwide availability of gene
sequencing makes it the most important diagnostic test in
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NP-C, and recent developments in sequencing technology
have reduced costs and improved turnaround times.
We suggest that patients with a suspicion of NP-C
should undergo NPC1 and NPC2 gene sequencing as
standard. Identification of two pathogenic mutations that
segregate in the family should be sufficient for at least an
initial diagnosis (Fig. 1). Further investigations in specia-
lised laboratories are recommended for patients in whom
only one pathogenic mutation is identified, and for those
with novel mutations. These investigations may include
molecular genetic approaches such as MLPA, RNA
sequencing, quantitative real-time PCR and western blot-
ting. Filipin staining of skin fibroblasts should also be
undertaken bearing in mind the possibility of an equivocal
result.
In the near future, it is expected that LC–MS/MS
methods will become available and will complement
molecular genetics, thus affording accurate, early and fast
diagnosis in all patients with NP-C.
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